Dawn Joyce M.P.H.

Vice President

B.A., Wellesley College; M.P.H. U.C. Berkeley

(510) 847-2900

Dawn Joyce joined Wynne Health Group after 10 years of government service and program implementation at the federal, state, and local levels focused on public health, health systems, and health policy. As both an in-house manager and trusted consultant, Dawn has provided comprehensive services to healthcare, human services, and public health stakeholders including advocacy organizations, think tanks, multi-stakeholder partnerships, insurance alliances, and public health departments.

Dawn’s strong combination of government and program implementation experience uniquely positions her to understand client’s needs and maximize the positive impact of understanding health policy. Prior to joining Wynne Health, she founded Policies & Partnerships for Health, a consultancy providing analysis, research, and strategic counsel to clients such as the Colorado Department of Health Care Policy and Financing, the Boulder County Health Improvement Collaborative, the Keystone Policy Center, and the Community First Foundation. In this capacity, she fostered a proven track record for helping clients understand the complexity of health policy, jointly develop a vision, and decipher a pathway toward successful change.

Prior to establishing her consulting firm, Dawn was Health Systems Unit Director with the Colorado Department of Public Health and Environment. She has also worked extensively with Amigos de las Americas and Save the Children, and was a Graduate Student Researcher with the Bixby Center for Global Reproductive Health. Early in her policy career, Dawn was a staff assistant in the office of U.S. Senator Dianne Feinstein. She also gained hands-on political experience as a field organizer for the successful campaign of U.S. Senator Ken Salazar.

Dawn received her Bachelor of Arts degree from Wellesley College and a Master of Public Health from the University of California, Berkeley, where she focused on maternal and child health, health communications, and epidemiology. She lives in Boulder, Colorado with her husband, and two young children.

Washington Begins Horse Trading over Next Phase of COVID-19 Aid

California-Health-Care-Foundation 400x200
Negotiations in Congress over the next COVID-19 aid plan are expected to start after the July 4 break, and a package is likely to pass before Congress adjourns for the August recess. In total, we expect the bill to include up to $3 trillion in funding based on the House proposal, the HEROES Act. The Senate, House, and Trump administration proposals are starkly different, so the exact contents of the final legislation remain to be seen. The main political pull is essentially between those who want the aid to be mostly about funding economic recovery and those who would focus on boosting medical care and public health....
+ Read More

The Benefits of Telehealth During a Pandemic — and Beyond

Commonwealth-Fund 400x200
Medicare began including telehealth as a benefit nearly 20 years ago, but has used it only on a limited basis. This was in large part because of statutory restrictions that limited coverage to rural beneficiaries who received care by certain practitioners in designated sites, which did not include the beneficiary’s home. Now, in the wake of the COVID-19 outbreak, policymakers are looking to telehealth as critical to ensuring that Medicare beneficiaries can still access care while reducing the risk of coronavirus transmission....
+ Read More

You’re Doing It Wrong: What Changes In Medicaid And SNAP Reveal About The Trump Administration’s Investment In The Social Determinants Of Health

The Department of Health and Human Services (HHS) defines the social determinants of health as the “conditions in the environments in which people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks.” The concept, which comes from the global public health field, is at its best when it is understood to encompass an individual’s social location—their race, ethnicity, sex, class, ability, orientation, culture, and how each of these identities impact them in their community context. It was created to identify and serve the most vulnerable among the world’s populations and to address the inequities that disproportionately impact their lives and their health. ...
+ Read More

Five Reasons Medicare For All (Or Anything Like It) Won’t Pass In 2021

While conventional wisdom, and some presidential candidates, have already begun to temper these expectations, my goal here is to document five reasons why Medicare for All (M4All), Medicare buy-in, or federal public option legislation cannot pass in the near future. My hope, in doing so, is that we Democrats spare ourselves the precious time, internal acrimony, and political fallout that Republicans faced when their lofty ACA repeal promises went unfulfilled....
+ Read More

CMS Releases Advance Notice For Medicare Advantage And Part D Plans

Last week, the Centers for Medicare & Medicaid Services (CMS) released Part II of its Advance Notice of Methodological Changes for Medicare Advantage (MA) Capitation Rates and Part D Payment Policies for Calendar Year (CY) 2021 (fact sheet). The agency also released its proposed rule on policy and technical changes to MA and Part D for CYs 2021 and 2022 (fact sheet). A press release for both developments is available here. This post focuses on summarizing the Advance Notice component of this package of policies....
+ Read More

The Forecast for Legislative and Regulatory Activity on Health Care in 2020

As the impeachment trial has concluded with the acquittal of President Trump, Congress is now returning to some sense of normalcy. On the health care front, policymakers will need to secure a deal relatively quickly on top-priority issues like prescription drug pricing and surprise medical billing. The apparent deadline for final legislation in both regards is the May 22 expiration date of funding for several public health programs (e.g., community health centers), which many are eyeing as the last real opportunity for meaningful reform this year. Many doubt whether Congress will produce much after that date because of compressed schedules to accommodate party conventions and an extended recess in October. However, health care is in the forefront of voters’ minds. ...
+ Read More

New Legislation to Control Drug Prices: How Do House and Senate Bills Compare? An Update

Commonwealth-Fund 400x200
As Congress grapples with an evolving impeachment inquiry, lawmakers have remained focused on lowering prescription drug costs. In December, the House passed the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) by a 230–192 vote, largely along party lines with no Democratic defections. House Democratic leaders successfully assuaged grumblings from the Congressional Progressive Caucus that H.R. 3 did not go far enough by doubling the minimum number of drugs subject to price negotiation, among other policy changes....
+ Read More

Surprise Medical Billing Might Get a Hybrid Solution

California Health Care Foundation Logo
Reaching a consensus on how to protect patients from surprise medical bills has eluded Congress for most of the year even though members in both parties and chambers are highly motivated to find a fix. With an agreement reached over the December 7–8, 2019, weekend, a solution seems closer than it has in a long time....
+ Read More

A Look Inside The Hospital Transparency Final Rule

On November 15, 2019, The Centers for Medicare & Medicaid Services (CMS) finalized a controversial set of requirements for the disclosure of hospital pricing data to degrees heretofore not seen. Stemming from the recent transparency Executive Order (EO), the final rule reflects the current administration’s overall push to increase pricing and cost transparency throughout the health care system. While the original proposal faced substantial backlash from stakeholders, CMS’ final decision is nearly identical to what the agency originally proposed....
+ Read More

New Legislation to Control Drug Prices: How Do House and Senate Bills Compare?

Commonwealth-Fund 400x200
The following tables compare H.R. 3 based on the legislative text advanced by key committees of jurisdiction and key provisions of related proposals: the Prescription Drug Pricing Reduction Act of 2019 (S. 2543), advanced by the Senate Finance Committee in July; and the Advanced Notice of Proposed Rulemaking (ANPRM): Medicare Program, IPI Model for Medicare Part B Drugs, issued by the Centers for Medicare and Medicaid Services last October....
+ Read More